Continuous glucose monitoring: indications, data interpretation and making therapeutic decisions

Authors

  • León Litwak Italian Hospital of Buenos Aires, Autonomous City of Buenos Aires, Argentina
  • Nancy Carreño Argentina Diabetes Foundation, Autonomous City of Buenos Aires, Argentina
  • Rodrigo Carnero Río Cuarto Medical Institute, Córdoba, Argentina
  • Alejandro Dain Reina Fabiola de Córdoba University Clinic, Córdoba, Argentina
  • Luis Grosembacher Italian Hospital of Buenos Aires, Autonomous City of Buenos Aires, Argentina
  • Carla Musso Favaloro Foundation, Autonomous City of Buenos Aires, Argentina
  • Adrián Proietti Integral Institute of Diabetes and Applied Technology (IDTA), Autonomous City of Buenos Aires, Argentina
  • Lucas Rista Diabetes and Nutrition Center of Rosario, President of the Paul Langerhans Foundation, Santa Fe, Argentina
  • Gabriela Rovira British Hospital of Buenos Aires, Autonomous City of Buenos Aires, Argentina
  • Graciela Rubin Private University Hospital of Córdoba, Córdoba, Argentina
  • María Ruiz Center for Diabetes and Metabolic Diseases (CODIME), Autonomous City of Buenos Aires, Argentina
  • Antonio Saleme Favaloro University, Sanatorio Santa Fe, Santa Fe, Argentina
  • Liliana Trifone Ricardo Gutiérrez Children's Hospital, Autonomous City of Buenos Aires, Argentina
  • José Costa Gil Favaloro University, Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v54i3.455

Keywords:

diabetes, continuous glucose monitoring, glycemic control, intensive insulin therapy

Abstract

The tools to assess the degree of glycemic control were modified lately. Glycosylated Hemoglobin (HbA1c), the gold standard, reflects the glycemic control of the last 3 months retrospectively, without expressing glycemic variability. Self-blood glucose monitoring (SBGM) provides immediate and prospective information, but has little glycemic data to generate representative averages and standard deviations. It does not detect trends and has limitations to obtain nocturnal data or during physical activity. It is invasive and often rejected. On the contrary, continuous glucose monitoring (CGM), allows to measure glucose instantly, shows your trends and variability continuously, incorporating new control metrics.

Author Biographies

León Litwak, Italian Hospital of Buenos Aires, Autonomous City of Buenos Aires, Argentina

Endocrinologist, Endocrinology, Metabolism and Nuclear Medicine Service

Nancy Carreño, Argentina Diabetes Foundation, Autonomous City of Buenos Aires, Argentina

Specialist in Medical Clinic, Nutrition and Diabetes, Fundación Argentina Diabetes; Secretary of the Innovation Committee in Diabetes, Argentine Diabetes Society (SAD)

Rodrigo Carnero, Río Cuarto Medical Institute, Córdoba, Argentina

Specialist in General Medicine, Master in Clinical Endocrinology; Head of the Endocrinology and Diabetes Service, Río Cuarto Medical Institute, Diabetes Innovation Committee, Argentine Diabetes Society (SAD)

Alejandro Dain, Reina Fabiola de Córdoba University Clinic, Córdoba, Argentina

Doctor of Medicine, Surgery, specialist in Internal Medicine, Clinical Nutrition and Diabetology, University Professor; Associate Professor of Histology, Villa María National University and Professor of the National University of Córdoba (UNC); Coordinator of the Master in Diabetes and Nutrition (UNC, Nutrition Area); Staff Reina Fabiola de Córdoba University Clinic

Luis Grosembacher, Italian Hospital of Buenos Aires, Autonomous City of Buenos Aires, Argentina

Endocrinologist; Head of the Diabetes Section, Endocrinology, Metabolism and Nuclear Medicine Service

Carla Musso, Favaloro Foundation, Autonomous City of Buenos Aires, Argentina

Endocrinologist; Diabetes Area Coordinator

Adrián Proietti, Integral Institute of Diabetes and Applied Technology (IDTA), Autonomous City of Buenos Aires, Argentina

Specialist in Internal Medicine; Endocrinologist; Medical Director of the Integral Institute of Diabetes and Applied Technology (IDTA); Director of the Course on Technology applied to Diabetes, Argentine Society of Diabetes (SAD)

Lucas Rista, Diabetes and Nutrition Center of Rosario, President of the Paul Langerhans Foundation, Santa Fe, Argentina

Magister in Diabetes; Member of the Innovation Committee and President of the Litoral Chapter, Argentine Diabetes Society (SAD), Diabetes and Nutrition Center of Rosario; President of the Paul Langerhans Foundation

Gabriela Rovira, British Hospital of Buenos Aires, Autonomous City of Buenos Aires, Argentina

Endocrinologist; Coordinator of the Technology and Diabetes Area, Endocrinology, Metabolism, Nutrition and Diabetes Service

Graciela Rubin, Private University Hospital of Córdoba, Córdoba, Argentina

Internist Physician, expert in Diabetes, Diabetology and Nutrition Service, Private University Hospital of Córdoba; Coordinator of the Diabetes Innovation Committee, Argentine Diabetes Society (SAD)

María Ruiz, Center for Diabetes and Metabolic Diseases (CODIME), Autonomous City of Buenos Aires, Argentina

Family Physician specialized in Diabetes, Consultant Center for Diabetes and Metabolic Diseases (CODIME); Coordinator of the Course on Technology Applied to Diabetes, Argentine Diabetes Society (SAD)

Antonio Saleme, Favaloro University, Sanatorio Santa Fe, Santa Fe, Argentina

Magister in Diabetes, Postgraduate Faculty of Medical Sciences, Favaloro University; Specialist in Medical Clinic; Member of the Innovation and Diabetes Committee, Argentine Diabetes Society (SAD); Head of the Endocrinology and Metabolism Service

Liliana Trifone, Ricardo Gutiérrez Children's Hospital, Autonomous City of Buenos Aires, Argentina

Pediatrician Specialist in Nutrition; Head of the Nutrition and Diabetes Section

José Costa Gil, Favaloro University, Autonomous City of Buenos Aires, Argentina

Doctor of Medicine, Graduate Faculty of Medical Sciences

References

I. American Diabetes Association. Glycemic Targets: Standards of medical care in diabetes-2020. Diabetes Care 2020 Jan; 43(Supplement 1):S66-S76.

II. Litwak LE, Mileo VR, Álvarez A, Gutman RA. Autocontrol de la glucemia capilar: evaluación del resultado a largo plazo (3 a 7 años). Medicina (Buenos Aires) 1999; 59:71-78.

III. Commendatore VF, Linari MA, Dieuzeide G, Ferraro M, Lapertosa S, Puchulu F, et al. Automonitoreo y monitoreo de glucosa y cetonas en la persona con diabetes. Rev Soc Arg Diab 2007; 41:95-104.

IV. American Diabetes Association. Diabetes Technology: Standards of Medical Care in Diabetes 2020. Diabetes Care 2020; S77-S88.

V. Advani A. Positioning time in range in diabetes management. Diabetologia 2020; 63:242-252.

VI. U.S. Food and Drug Administration. FreeStyle Libre Flash Glucose Monitoring System: summary of safety and effectiveness data (SSED). Disponible en:. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160030. Acceso: 06/07/ 2017.

VII. Bailey TS, Grunberger G, Bode BW, Handelsman Y, Hirsch IB, Jovanovič L, et al. American Association of Clinical Endocrinologists and American College of Endocrinology. 2016 Outpatient glucose monitoring consensus statement. Endocr Pract 2016; 22:231-261.

VIII. Sherr J, Tauschmann M, Battelino T, Bock M, Forlenza G, Roman R, Hood K, Maahs D. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes Technologies. Pediatric Diabetes 2018; 19 (Suppl.27):302-325.

IX. American Diabetes Association. Diabetes Technology: Standars of medical care in diabetes-2019. Diabetes Care 2019; 42(Suppl. 1):S71-80.

X. Laffel L, Aleppo G, Buckingham G, Forlenza G, Rasbach L, Tsalikian E, et al. A practical approach to using trend arrows on the Dexcom G5 CGM system to manage children and adolescents with diabetes. J Endocr Soc 2017 Dec; 1(12):1461-1476.

XI. Murphy HR, Rayman G, Duffield K, et al. Changes in the glycemic profiles of women with type 1 and type 2 diabetes during pregnancy. Diabetes Care 2007 Nov; 30(11):2785-2791.

XII. Kröger J, Fasching P, Hanaire H, et al. Three European retrospective real-world chart review studies to determine the effectiveness of flash glucose monitoring on HbA1c in adults with type 2 diabetes. Diabetes Ther 2020 Jan;11(1):279-291.

XIII. Evans M, Welsh Z, Ells S, et al. The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of Clinical Trials and Real-World Observational Studies. Diabetes Ther 2020 Jan; 11(1):83-95.

XIV. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019; 42(8):1593-1603.

XV. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile (AGP). Diabetes Technol Ther 2013; 15:198-211.

XVI. Xing D, Kollman C, Beck RW, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011; 13:351-358.

XVII. Riddlesworth TD, Beck RW, Gal RL, et al. Optimal sampling duration for continuous glucose monitoring to determine long-term glycemic control. Diabetes Technol Ther 2018; 20:314-316.

XVIII. Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The fallacy of average: how using HbA1c al one to assess glycemic control can be misleading. Diabetes Care 2017; 40:994-999.

XIX. Bergenstal RM, Beck RW, Close KL, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care 2018; 41:2275-2280.

XX. American Diabetes Association. Diabetes Technology: Standards of medical care in diabetes-2019. Diabetes Care 2019; 43(suppl 1):S1-S212.

XXI. Feig DS, Donovan LE, Corcoy R, et al.; CONCEPTT Collaborative Group. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet 2017; 390:2347-2359.

XXII. Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care 2018; 41:2370-2376.

XXIII. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care 2019; 42:400-405.

XXIV. Beck RW, Bergenstal RM, Cheng P, et al. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol 2019 Jan (Epub ahead of print). Doi:10.1177/1932296818822496.

XXV. Vigersky RA, Mc Mahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther 2019; 21:81-85.

XXVI. Rodbard D. Glucose variability: a review of clinical applications and research developments. Diabetes Technol Ther 2018; 20(suppl 2):S25-S215.

XXVII. Monnier L, Colette C, Wojtusciszyn A, Dejager S, Renard E, Molinari N, et al. Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care 2017 Jul; 40:832-838.

XXVIII. Rodbard D. Hypo and hyperglycemia in relation to the mean, standard deviation, coefficient of variation, and nature of the glucose distribution. Diabetes Technol Ther 2012; 14:868-876.

XXIX. Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care 2017; 40:1631-1640.

XXX. Litwak L, Querxoli I, Musso C, Dain A, Houssay S, Costa Gil JE. Monitoreo continuo de glucosa, utilidad e indicaciones. Medicina (Buenos Aires) 2019; 79:44-52.

XXXI. Ziegler R, von Sengbusch S, Kröger J, Schubert O, Werkmeister P, Deiss D, Siegmund T. Therapy adjustments based on trend arrows using continuous glucose monitoring systems. J Diabetes Sci Technol 2019; 1-11.

XXXII. Borot S, Benhamou P, Atlan C, Bismuth E, Bonnemaison E, Catargi B, et al. Practical implementation, education and interpretation guidelines for continuous glucose monitoring: A French position statement. Diabetes Metab 2018; 44:61-72.

XXXIII. Aleppo G, Laffel L, Ahmann A, Hirsch I, Kruger D, Peters A, et al. Un enfoque práctico para usar las flechas de tendencia en el sistema Dexcom G5 CGM para el manejo de adultos con diabetes. Journal of the Endocrine Society 2017 Dec; 1(12):1445-1460.

XXXIV. Yaron M, Roitman E, Aharon-Hananel G, Landau Z, Ganz T, Yanuv I, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care 2019 Jul; 42(7):1178-1184.

XXXV. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8:55-73.

XXXVI. Website plataformas digitales de FreeStyle Libre. Disponible en: www.freestylelibre.com.ar, www.libreview.com

XXXVII. Hirsch I, Battelino T, Peters AL, Chamberlain JJ, Aleppo G, Bergenstal R. Role of continuous glucose monitoring in diabetes treatment. Arlington (VA): American Diabetes Association; 2018 Aug.

XXXVIII. Ajjan RA, Cummings MH, Jennings P, Leelarathna L, Rayman G, Wilmot EG. Optimising use of rate-of-change trend arrows for insulin dosing decisions using the FreeStyle Libre flash glucose monitoring system. Diab Vasc Dis Res 2019 Jan; 16(1):3-12.

XXXIX. Chico A, Aguilera E, Ampudia-Blasco FJ, Bellido V, Cardona-Hernández R, Escalada FJ, et al. Clinical approach to flash glucose monitoring: an expert recommendation. J Diabetes Sci Technol 2020 Jan;14(1):155-164.

Downloads

Published

2023-01-10

How to Cite

Litwak, L., Carreño, N., Carnero, R., Dain, A., Grosembacher, L., Musso, C., Proietti, A., Rista, L., Rovira, G., Rubin, G., Ruiz, M., Saleme, A., Trifone, L., & Costa Gil, J. (2023). Continuous glucose monitoring: indications, data interpretation and making therapeutic decisions. Journal of the Argentine Society of Diabetes, 54(3), 140–154. https://doi.org/10.47196/diab.v54i3.455

Issue

Vol. 54 No. 3 (2020): September/December 2020

Section

Recommendations

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.

 

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>